Upon completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences and will be delisted from the Nasdaq
The therapy also delivered significant improvements in key liver enzyme markers
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
